Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEAB | ISIN: US15117B2025 | Ticker-Symbol: TCE2
Tradegate
06.06.25 | 21:40
18,700 Euro
-0,53 % -0,100
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLDEX THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CELLDEX THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
18,50018,90006.06.
18,60018,90006.06.

Aktuelle News zur CELLDEX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCelldex Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
FrCelldex Therapeutics ernennt neues Vorstandsmitglied3
FrCelldex Therapeutics appoints new board member1
FrCelldex Therapeutics, Inc.: Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors2
FrCelldex Therapeutics, Inc. - 8-K, Current Report1
09.05.Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain3
CELLDEX THERAPEUTICS Aktie jetzt für 0€ handeln
08.05.Celldex Therapeutics, Inc. - 10-Q, Quarterly Report5
08.05.Celldex Therapeutics, Inc. - 8-K, Current Report2
06.05.Cantor Fitzgerald maintains Celldex stock Overweight with $67 target4
28.04.Analyst Expectations For Celldex Therapeutics' Future21
20.03.7 Analysts Have This To Say About Celldex Therapeutics11
20.03.Morgan Stanley sets Celldex stock overweight with $46 target18
03.03.Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug360WASHINGTON (dpa-AFX) - Celldex Therapeutics, Inc (CLDX) Monday reported positive preclinical data for CDX-622, a bispecific antibody targeting inflammation and fibrosis through dual inhibition...
► Artikel lesen
03.03.Celldex Therapeutics, Inc.: Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025202- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics...
► Artikel lesen
01.03.Celldex Therapeutics, Inc.: Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025109- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life...
► Artikel lesen
28.02.Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics17
27.02.Celldex GAAP EPS of -$0.71 beats by $0.02, revenue of $1.18M misses by $0.07M12
27.02.Celldex Therapeutics, Inc.: Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update204Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment...
► Artikel lesen
27.02.Celldex Therapeutics, Inc. - 10-K, Annual Report-
27.02.Celldex Therapeutics, Inc. - 8-K, Current Report-
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1